1. Home
  2. UFCS vs AVLN Comparison

UFCS vs AVLN Comparison

Compare UFCS & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Fire Group Inc.

UFCS

United Fire Group Inc.

HOLD

Current Price

$51.97

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$27.96

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UFCS
AVLN
Founded
1946
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
1995
2026

Fundamental Metrics

Financial Performance
Metric
UFCS
AVLN
Price
$51.97
$27.96
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$40.50
N/A
AVG Volume (30 Days)
146.0K
520.1K
Earning Date
05-05-2026
N/A
Dividend Yield
2.01%
N/A
EPS Growth
87.45
N/A
EPS
1.15
N/A
Revenue
$1,386,412,000.00
N/A
Revenue This Year
$11.80
N/A
Revenue Next Year
$8.77
N/A
P/E Ratio
$45.17
N/A
Revenue Growth
10.62
N/A
52 Week Low
$25.81
$27.33
52 Week High
$54.42
$33.32

Technical Indicators

Market Signals
Indicator
UFCS
AVLN
Relative Strength Index (RSI) 62.72 32.04
Support Level $34.84 $27.37
Resistance Level $54.42 $29.48
Average True Range (ATR) 1.70 2.48
MACD -0.11 -0.30
Stochastic Oscillator 64.56 14.40

Price Performance

Historical Comparison
UFCS
AVLN

About UFCS United Fire Group Inc.

United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: